Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Tailoring Obesity Treatment Trial
NCT06619015 · Esbjerg Hospital - University Hospital of Southern Denmark · PHASE2/PHASE3 · withdrawn · last registry update 2026-04-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “suspended by the danish medical agency” | – | Registry record, Esbjerg Hospital - University Hospital of Southern Denmark |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CALCR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-06-18Phase 3 first posted: Tanta University, Calcitonin (NCT07655804)
- 2026-06-12Phase 3 first posted: Rigmor Højland Jensen, Eptinezumab + Placebo (NCT07645833)
- 2026-03-05Results posted on the registry: Oregon Health and Science University, a drug against CALCR (NCT06422325)
- 2026-02-12Results posted on the registry: The University of Texas Health Science Center, Houston, Crofelemer (NCT03898856)
- 2025-12-16Results posted on the registry: Pfizer, Rimegepant 75mg daily dosing + Rimegepant 75mg every other day dosing (NCT05217927)
- 2025-11-17Also stopped (terminated): Centre Hospitalier Departemental Vendee, a drug against CALCR (NCT01977079)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision